Novel human lysosomal protein and methods of its use
OwnerPeter Lobel, David Sleatinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerPeter Lobel, David Sleatinventors
Estimating the term…
The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.
An isolated CLN2 protein with the following characteristics:
A purified nucleic acid encoding CLN2, or a fragment thereof having at least 15 nucleotides.
A method for treating LINCL in an animal by increasing the level of CLN2 in cells.
A method for measuring CLN2 activity in a biological sample based on the amount of CLN2 pepstatin-insensitive carboxyl protease activity relative to normal controls in a biological sample.
A method for identification of lysosomal proteins based on the presence of mannose 6-phosphate glycosylation and comprising the following steps:
Dependencies are inferred from the claim text.